» Articles » PMID: 35396346

ROCK2-induced Metabolic Rewiring in Diabetic Podocytopathy

Abstract

Loss of podocytes is a common feature of diabetic renal injury and a key contributor to the development of albuminuria. We found that podocyte Rho associated coiled-coil containing protein kinase 2 (ROCK2) is activated in rodent models and patients with diabetes. Mice that lacked ROCK2 only in podocytes (PR2KO) were resistant to albuminuria, glomerular fibrosis, and podocyte loss in multiple animal models of diabetes (i.e., streptozotocin injection, db/db, and high-fat diet feeding). RNA-sequencing of ROCK2-null podocytes provided initial evidence suggesting ROCK2 as a regulator of cellular metabolism. In particular, ROCK2 serves as a suppressor of peroxisome proliferator-activated receptors α (PPARα), which rewires cellular programs to negatively control the transcription of genes involved in fatty acid oxidation and consequently induce podocyte apoptosis. These data establish ROCK2 as a nodal regulator of podocyte energy homeostasis and suggest this signaling pathway as a promising target for the treatment of diabetic podocytopathy.

Citing Articles

Conditional deficiency of Rho-associated kinases disrupts endothelial cell junctions and impairs respiratory function in adult mice.

Akamine T, Terabayashi T, Sasaki T, Hayashi R, Abe I, Hirayama F FEBS Open Bio. 2024; 14(6):906-921.

PMID: 38604990 PMC: 11148122. DOI: 10.1002/2211-5463.13802.


Deletion of podocyte Rho-associated, coiled-coil-containing protein kinase 2 protects mice from focal segmental glomerulosclerosis.

Matoba K, Nagai Y, Sekiguchi K, Ohashi S, Mitsuyoshi E, Shimoda M Commun Biol. 2024; 7(1):402.

PMID: 38565675 PMC: 10987559. DOI: 10.1038/s42003-024-06127-3.


Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy.

Jiang H, Shen Z, Zhuang J, Lu C, Qu Y, Xu C Front Immunol. 2024; 14:1335936.

PMID: 38288116 PMC: 10822972. DOI: 10.3389/fimmu.2023.1335936.

References
1.
Yamamoto T, Nakamura T, Noble N, Ruoslahti E, Border W . Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993; 90(5):1814-8. PMC: 45970. DOI: 10.1073/pnas.90.5.1814. View

2.
Peng H, Li Y, Wang C, Zhang J, Chen Y, Chen W . ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy. Sci Rep. 2016; 6:20304. PMC: 4740844. DOI: 10.1038/srep20304. View

3.
Etienne-Manneville S, Hall A . Rho GTPases in cell biology. Nature. 2002; 420(6916):629-35. DOI: 10.1038/nature01148. View

4.
Matoba K, Kawanami D, Okada R, Tsukamoto M, Kinoshita J, Ito T . Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α. Kidney Int. 2013; 84(3):545-54. DOI: 10.1038/ki.2013.130. View

5.
Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500):1849-61. DOI: 10.1016/S0140-6736(05)67667-2. View